Fujita Kazuma, Suzuki Akifumi, Nagahama Mitsuji, Sugino Kiminori, Masaki Chie, Ito Koichi, Miura Masatomo
Department of Pharmacy, Akita University Hospital, Akita, Japan.
Department of Surgery, Ito Hospital, Shibuya, Japan.
Drugs Real World Outcomes. 2025 Mar;12(1):153-160. doi: 10.1007/s40801-024-00467-6. Epub 2024 Dec 1.
Kampo medicines are often used in Japan as therapy for the side effects induced by oral kinase inhibitors. However, the pharmacokinetic interactions between Kampo medicines and oral kinase inhibitors such as lenvatinib have not been studied.
We investigated the effects of Kampo medicines (rikkunshito, shakuyakukanzoto and goreisan) on the steady-state plasma trough concentration (C) of lenvatinib in patients with thyroid cancer.
Thirty-nine patients receiving lenvatinib therapy at Ito Hospital between May 2015 and December 2019 were enrolled. The mean C of lenvatinib with Kampo medicine, at the same dose as before initiating Kampo medicines, was used.
After the repeated administration of rikkunshito (n = 21), shakuyakukanzoto (n = 10) or goreisan (n = 8), the mean C of lenvatinib and the laboratory test values of patients did not change significantly. In contrast to rikkunshito, which alleviates emesis by enhancing gastric emptying, the C values of lenvatinib with a proton pump inhibitor (PPI) (n = 16) or histamine H receptor antagonist (H2RA) (n = 4) were significantly lower than the C values without a PPI or H2RA (P = 0.007). The mean (range) change rate of the C of lenvatinib with a PPI or H2RA versus without a PPI or H2RA was 88.6% (69.9-115%), and was significantly greater than the change rate for rikkunshito (P = 0.029). There was no significant difference between the C of lenvatinib with a prokinetic agent (n = 7) versus without a prokinetic agent (P = 0.365).
Although these Kampo medicines are reported to inhibit drug-metabolizing enzymes and drug transporters, the risk of drug interactions for patients receiving lenvatinib therapy is low. Patients should feel confident that they can receive Kampo medicines as supportive care for lenvatinib therapy without a risk of drug interactions that could affect treatment efficacy.
汉方药在日本常被用于治疗口服激酶抑制剂引起的副作用。然而,汉方药与乐伐替尼等口服激酶抑制剂之间的药代动力学相互作用尚未得到研究。
我们研究了汉方药(理气剂、芍药甘草汤和五苓散)对甲状腺癌患者乐伐替尼稳态血浆谷浓度(C)的影响。
纳入2015年5月至2019年12月在伊东医院接受乐伐替尼治疗的39例患者。使用与开始服用汉方药之前相同剂量的乐伐替尼与汉方药联合时的平均C值。
重复服用理气剂(n = 21)、芍药甘草汤(n = 10)或五苓散(n = 8)后,患者乐伐替尼的平均C值和实验室检查值未发生显著变化。与通过增强胃排空来缓解呕吐的理气剂不同,使用质子泵抑制剂(PPI)(n = 16)或组胺H受体拮抗剂(H2RA)(n = 4)时乐伐替尼的C值显著低于未使用PPI或H2RA时的C值(P = 0.007)。使用PPI或H2RA时乐伐替尼C值相对于未使用PPI或H2RA时的平均(范围)变化率为88.6%(69.9 - 115%),且显著大于理气剂的变化率(P = 0.029)。使用促动力剂(n = 7)与未使用促动力剂时乐伐替尼的C值之间无显著差异(P = 0.365)。
尽管据报道这些汉方药可抑制药物代谢酶和药物转运体,但接受乐伐替尼治疗的患者发生药物相互作用的风险较低。患者应放心,他们可以接受汉方药作为乐伐替尼治疗的支持性护理,而不会有影响治疗效果的药物相互作用风险。